DeBinge provides evidence-based educational resources, expert commentary and information relating to addiction treatment, relapse prevention, recovery and long-acting naltrexone. This newsroom is designed for journalists, researchers, podcasters, universities, healthcare professionals and others seeking clearly sourced information about these subjects.
Recent DeBinge announcements, research-related updates, educational releases and media developments.
September 26, 2026
Published first-in-human data and two recruiting U.S. Phase 1 studies show continued development of implantable naltrexone, while long-acting naltrexone implants remain investigational in the United States.
September 26, 2026
A source-verified review of current U.S. development, including published Phase 1 evidence, recruiting implant programs, NIH/NIDA support and FDA regulatory status.
September 26, 2026
Verified interviews, podcast appearances, conference contributions and external media coverage involving DeBinge or its contributors.
Official DeBinge press releases covering organisational developments, research-related announcements, educational initiatives, events and other verified news.
Each release should have a permanent URL, publication date, modification date where relevant, clearly identified publisher and appropriate source links.
View All Press ReleasesUpdates relating to published studies, clinical research, relapse prevention, naltrexone, substance-use treatment and areas of emerging evidence.
Explore DeBinge research summaries and links to primary scientific literature relevant to addiction treatment and relapse prevention.
Visit the Research LibraryFollow new research developments and contextual explanations intended for journalists, clinicians and researchers.
View Research UpdatesDeBinge can help journalists identify appropriate professional perspectives on addiction treatment, relapse prevention, substance misuse and related subjects.
Consultant Psychiatrist specialising in substance misuse and addiction.
His profile provides professional background information for journalists and others researching addiction medicine and substance misuse.
View Dr Fergus Law’s profileBackground information relating to Dr George O’Neill and his work concerning long-acting naltrexone is available through the DeBinge expert resource section.
Journalists should refer to primary research and source documentation when reporting specific study findings.
View Dr George O’Neill resourceVerified external interviews, podcast appearances, conference contributions and editorial coverage involving DeBinge or its contributors can be collected in this archive.
Only genuine published appearances should be listed. Each item should link directly to the original publisher, broadcaster, university, podcast or conference source.
View Media CoverageStart with the subject area most relevant to your reporting. Clinical or statistical claims should always be checked against the original scientific source.
Background information about treatment pathways, continuing care and recovery support.
Explore DeBinge resourcesEducational resources examining relapse risk, cravings and longer-term recovery planning.
Explore relapse preventionBackground information about long-acting naltrexone, treatment considerations and supporting research.
Explore long-acting naltrexoneGuidance on interpreting treatment outcomes, retention measures, abstinence definitions and reporting standards.
Understand treatment evidenceAccess research summaries and primary-source references relevant to addiction treatment and naltrexone.
Open Research LibraryReporting guidance, key terminology and source pathways for addiction-related journalism.
Open Journalist ResourcesJournalists, podcasters, researchers, universities and healthcare publications may contact DeBinge to request interviews or background commentary.
Please provide your organisation, intended subject, questions, format and deadline. Availability depends on the subject and the appropriate contributor.
Submit an Interview RequestJournalists and publishers should use approved materials in their intended editorial context and should not imply endorsement, affiliation or clinical conclusions that DeBinge has not stated.
Access the Media KitDeBinge provides information and treatment-related resources concerning addiction recovery, relapse prevention and long-acting naltrexone.
DeBinge is located in Nassau, The Bahamas. References to U.S. cities, states or other international locations within educational content do not mean that DeBinge operates a treatment facility in those locations.
Read more about DeBingeDeBinge newsroom materials are provided for general educational, journalistic and informational purposes. They are not a substitute for individual medical assessment, diagnosis or treatment.
Treatment suitability must be determined by appropriately qualified clinicians. Treatment outcomes vary between individuals, and no treatment can guarantee recovery, abstinence or prevention of relapse.
Regulatory status, approval, availability and clinical use of particular medicines, devices or treatment approaches may vary between jurisdictions.
Where scientific findings are discussed, journalists and researchers should consult the cited primary studies for methodology, limitations, patient populations and outcome definitions.
Journalists, broadcasters, researchers, universities, podcast producers and healthcare publications can contact DeBinge for verified background information, interview enquiries and media resources.
Contact DeBingeAsk about suitability, the medically supervised OLANI transition pathway, travel to Nassau and the year-long counselling programme.
